BL 1220
Alternative Names: BL-1220Latest Information Update: 28 Oct 2020
At a glance
- Originator Ben Gurion University; Hadassah Medical Organization
- Developer BioLineRx
- Class Hepatoprotectants; Sodium compounds
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Liver failure; Non-alcoholic steatohepatitis
Most Recent Events
- 28 Oct 2020 No recent reports of development identified for preclinical development in Liver-failure in Israel (PO)
- 28 Oct 2020 No recent reports of development identified for preclinical development in Non-alcoholic-steatohepatitis in Israel (PO)
- 31 Dec 2018 Discontinued - Preclinical for Liver failure in Israel (PO)